RevitaLash joins City of Hope to support breast cancer research and educational initiatives at the Gayle Brinkenhoff Breast Cancer Symposium
Since its inception nine years ago, RevitaLash Cosmetics has supported breast cancer research. This October RevitaLash joined City of Hope, a leading cancer research and treatment center, to hold the second annual Gayle Brinkenhoff Breast Cancer Symposium. On October 8, 2015, the symposium brought together research scientists and clinicians at the world-renowned City of Hope campus in Duarte, California. The event covered educational initiatives and topics including advanced breast cancer genetics, early detection and prevention strategies, new demographic and risk evaluation methods, innovative diagnostic and treatment modalities, recent advances in immunologic concepts, and potential future therapeutic regimes.
A committed supporter of philanthropic efforts related to breast cancer research and education, founder and CEO of RevitaLash Cosmetics, Michael Brinkenhoff, M.D., introduced the symposium. “It is my sincere hope that bringing together outstanding scientists and physicians will help shed light on this complex disease. My family’s greatest hope is that this symposium will be a valuable tool to better understand and treat this disease, and will serve as a memorial to someone who exemplified courage, compassion and grace throughout her life.” Gayle Brinkenhoff, co-founder of RevitaLash Cosmetics, was diagnosed with metastatic breast cancer at the age of 32. At last year’s symposium, Dr. Brinkenhoff announced that RevitaLash Cosmetics was committed to continuing this series of symposia at City of Hope for several years to come.
“This year’s symposium was both synergistic and energizing. Scientist and clinicians representing multiple disciplines came together to speak on leading-edge research and ideas for preventing, detecting and treating breast cancer,” said Linda Malkas, Ph.D., deputy director for research at City of Hope and the M.T. & B.A. Ahmadinia Professor in Molecular Oncology. “I came away from the symposium marveling at how differently we think about breast cancer today when compared to how we thought of it 20 years ago. The concepts and technology now being brought to bear on the disease are rapidly moving the field. For me, participating in this symposium is like watching breast cancer research and management movement in real-time.”
[Image courtesy of Behrman Communications]
